Investor Determination to Beat Cancer: NeOnc's Institutional Backing, Executive Commitment and Latest Capital Move Tell a Consistent Story

HOUSTON, Sept. 17, 2026 www.wallstreet-pr.com NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) is putting action behind its stated confidence. Following positive Phase 2a results and a 15M institutional transaction, CEO Amir Heshmatpour has continued increasing his personal stake. Today, the company announced another deliberate step: retiring its entire Series A convertible preferred for 6M, eliminating the potential dilution associated with those instruments.

The redemption used part of the proceeds from the recently announced institutional transaction. By acting before discounted conversion rights became available, NeOnc removed a provision that could have allowed conversion at 80% of the lowest closing price during the preceding five trading days, subject to a 1.00 floor. No common equity was issued in the redemption.

Since NeOnc reported positive NEO100 Phase 2a results on August 12, Heshmatpour has committed approximately 418.7K through open-market transactions. Founder, Chief Medical Officer and Chief Scientific Officer Dr. Thomas Chen has added approximately 210K, bringing their combined personal commitment during that period to roughly 629K.

Heshmatpour's latest addition came September 15. According to the company, his personal commitment over the past year now exceeds 1.5M.

For Wall Street PR, "Get In, I'm Buying!" captures the message conveyed by those actions: leadership is increasing its own exposure as the company advances its clinical programs.

NeOnc's NEO100 Phase 2a study reported six-month progression-free survival of 48.9%, exceeding its prespecified 20% historical benchmark, and median overall survival of 26.09 months. The study involved 24 patients with recurrent or progressive IDH1-mutant high-grade glioma.

Those figures represent something deeply personal: the possibility of more time with family. At the August readout, one participant had remained progression-free for approximately 19 months, and five participants remained on treatment. These encouraging findings came from a small, single-arm study and require further evaluation.

NEO100's self-administered, at-home intranasal approach also offers a potential benefit beyond drug delivery. Fewer trips for treatment administration could ease disruption for patients and caregivers and reduce some of the "white coat" anxiety associated with medical settings. That possibility remains distinct from a demonstrated benefit: quality-of-life analyses were still underway at the readout.

Alongside NEO100, NeOnc is advancing NEO212, an oral drug candidate that has completed Phase 1 dose escalation. Both programs draw on the company's patented technology platform, designed to address the challenge of delivering therapies to the brain.

Positive clinical findings, institutional backing, continued executive commitment and the removal of a specific dilution risk are beginning to tell a consistent story. In Wall Street PR's view, these developments bring together important ingredients for potential success. The next measure of that progress will be NeOnc's execution as it moves its therapies toward further clinical and regulatory milestones.

About Wall Street PR

Wall Street PR (WSTPR) is your premier destination for intelligent investor relations and financial communications. We deliver meticulously curated market intelligence, breaking news alerts, exclusive expert insights, and in-depth analysis to help investors and traders stay ahead in today's fast-moving markets. Whether you're a seasoned professional or an emerging investor, our platform provides hard-to-find information on earnings reports, regulatory shifts, market trends, and emerging opportunities, empowering you to make confident, well-informed decisions.

For companies, we specialize in high-impact Investor and Public Relations. We transform significant corporate milestones into compelling stories that resonate with investors, analysts, and the media. Our experienced team crafts strategic press releases and communications that cut through the noise, ensuring your achievements reach major outlets such as Forbes, Barron's, Investor's Business Daily, The Wall Street Journal, and beyond. With superior reach across more than 7,500 media outlets and strong relationships with influential financial newsletter writers, we maximize visibility and deliver your message clearly, whether celebrating success or navigating challenges.

Through targeted distribution, email newsletters, and strategic storytelling, Wall Street PR helps public companies build credibility, engage shareholders, and enhance market presence with precision and professionalism.

For further information, please email [email protected]

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. WSTPR is a third-party media provider that has been compensated $1,500 for this editorial by 247 MN on behalf of the company for providing ongoing NTHI editorial market outreach and other services. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further info https://wallstreet-pr.com/disclosure-nhti/.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

CONTACT:
Wall Street PR
[email protected]

Sources

Company announcement | Executive activity | Clinical results

COMTEX_492794104/2771/2026-09-17T09:46:48

You May Also Be Interested In

• SEC Issues Guidance to Tokenize Stocks After Clarity Act Failure, Robinhood (HOOD) Gains
• ReTo Eco-Solutions prices $15 million direct offering at $1.50 a share
• Trio-Tech wins $4.7M automotive semiconductor burn-in contract